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1. Introduction 
Every living organism tends to protect itself from harmful effects of pathogens or molecules 
of pathogenic origin that can disturb its well-being state. The first line of defence that comes 
into action upon encounter with the pathogen is referred to as innate immune defence 
mechanism. It had been a matter of great inquisitiveness how innate immune defence 
mechanism is able to render the body protected against such a diverse variety of pathogens. 
But with the discovery of germ line encoded pattern recognition receptors (PRRs) that can 
sense the pathogen associated molecular patterns (PAMPs), it is to an extent possible to 
answer the query, how innate immune system copes to recognise such a wide variety of 
micro-organisms and harmful microbial elements. PAMPs are usually of pathogenic origin 
and absent from the cells of host origin. PRRs can be transmembrane receptors like Toll like 
receptors (TLRs) (Beutler & Rietschel, 2003; Janeway & Medzhitov, 2002), C-type lectin 
receptors (CLRs) or these can be cytosolic receptors like Nod like receptors (NLRs) and Rig 
like helicases (RLRs). Every PRR is capable of recognising specific conserved molecular 
patterns on the micro-organism and later can start a downstream signalling process upon 
proper interaction of PAMP and PRR that leads to synthesis of effector molecules like 
antimicrobial peptides and pro-inflammatory cytokines that prevent the body from 
otherwise harmful microbes. 
In the late 90’s a protein was discovered in Drosophila named as Toll. Toll is a 
transmembrane receptor that is required for the establishment of proper dorso-ventral 
polarity during embryo formation in Drosophila (Hashimoto et al., 1988). Mutation in Toll 
gene results in a weird phenotype of the fruitflies. Later it was found that signalling 
pathways of Drosophila Toll and mammalian IL-1 receptor showed marked resemblance 
leading to the assumption that Toll may be involved in the regulation of immune responses. 
Now, it is well established that Toll signalling is required for the defence against Gram-
positive, Gram-negative bacterial and fungal infections. Toll is responsible for the 
production of Drosomycin, antifungal peptide (Lemaitre et al., 1996). Mutants lacking in 
components of Toll mediated signalling pathway (Toll, Spatzle, Tube, Pelle) are highly 
susceptible to fungal infections. A year succeeding the discovery of Toll in Drosophila, 
through database searches, Toll homologues in mammals as well were revealed known as 
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Toll like receptors (TLRs). TLRs recognise PAMPs of diverse origin from bacteria, virus, 
fungi, protozoa and others. TLRs can also sense the molecules that are generated within the 
host cells alarming a sort of danger signal like heat shock proteins (Hsp60, Hsp70, Hsp90), 
fibrinogen, surfactant protein A, heparin sulphate and others. Thirteen TLRs are reported so 
far, out of which TLR1 to TLR9 are conserved between human and mice. TLR10 is only 
functional in human while TLR11 is found to be functional only in mice. Upon interaction 
with their cognate ligands, TLRs either homodimerise or heterodimerise to further proceed 
the downstream signalling. 
2. Structure of TLRs 
Toll like receptors are type-I transmembrane receptors having an extracellular domain 
containing multiple leucine rich repeats (LRRs). There are about 19-25 tandem repeats of 
LRR motif each having 20-29 residue sequence motif LXXLXLXXNXLXXLXXXXXXXLXX 
where X is any amino acid (Bell et al., 2003). LRR motifs are responsible for interacting and 
recognising specific ligands and thereby initiating downstream signal transduction. LRRs 
are varied among different TLRs enabling them to sense a wide variety of PAMPs. 
Interaction of the pathogen with the LRR motif is supposed to take place at the concave side 
of the horse shoe shaped LRR motif. Mammalian TLRs are found to have homology with IL-
1 receptor in cytoplasmic domain known as Toll/IL-1R or TIR domain while extracellular 
regions are devoid of any homology having three immunoglobulin domains in IL-1R and 
LRR motifs in TLRs. TIR domain consists of about 200 amino acids (Slack et al., 2000) and is 
composed of five ǃ strands (ǃA, ǃB, ǃC, ǃD and ǃE) alternated with five ǂ helices (ǂA, ǂB, 
ǂC, ǂD and ǂE) (Xu et al., 2000) connected via 8 loops. Box1, Box2 and Box3 are three highly 
conserved regions found to be present in TIR domain. BB loop is formed when Box2 forms a 
loop connecting the second ǃ strand and ǂ helix. This BB loop is of primary importance in 
further downstream signalling because any single amino acid residue substitution in this 
loop can lead to the complete impairment of its function. In C3H/HeJ mice, a point 
mutation in BB loop replacing conserved proline leads to hypo-responsiveness to the LPS 
resulting in loss of function of BB loop (Poltorak et al., 1998). 
3. Distribution of TLRs 
TLRs are generally expressed on the cells of innate immune system like dendritic cells, 
monocytes and macrophages (Beutler & Rehli, 2002) that are likely to have interacted with 
the pathogen earlier. TLR expression is found to be highest on the phagocytic cells like 
tissue macrophages, neutrophils and dendritic cells. Macrophages express all TLRs except 
TLR3. However, not all TLRs are expressed by all cell types i.e. TLR expression is tissue 
specific eg. TLR5 is shown to be exclusively expressed on the intestinal epithelial cells’ 
basolateral surface. Also TLR expression may vary with the maturation stage of the cell, eg. 
TLR1, 2, 4 and 5 are shown to be expressed on the immature dendritic cells but there 
expression decreases as the cells undergo maturation. TLR3 is shown to be expressed only 
on mature dendritic cells. Yet tissue specific demarcation of TLR expression is not clear, it is 
observed that most of the tissues express atleast one type of TLR. Also TLR expression is 
found to be different in the two subsets of blood dendritic cells i.e. Myeloid dendritic cells 
express TLR1, 2, 4, 5 and 8 while plasmacytoid dendritic cell express TLR7 and TLR9 
exclusively. TLR2 and 4 are highly expressed on the surface of macrophages but are also 
reported to be expressed on the endothelial cells, smooth muscle cells, intestinal cells and  
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Fig. 1. Toll like receptors and IL-1R are transmembrane receptors both having a conserved 
region of about 200 amino acids in their cytoplasmic domain known as TIR domain. Three 
highly conserved regions in TIR domain are referred to as Box1, Box2 and Box3. TLRs and 
IL-1R though similar in their cytoplasmic domains are markedly different in their 
extracellular components; TLRs have LRR motif and IL-1R has Ig like domain 
extracellularly.  
others. Studies also indicate subcellular location of TLRs. TLR1, TLR2, TLR4, TLR5 and TLR6 
have been found to be expressed on the cell surface, as demonstrated by positive staining of 
the cell surface by specific antibodies and these recognize bacterial products while TLR3, 
TLR7, TLR8 and TLR9 have been shown to be expressed in intracellular compartments such as 
endosomes and recognize microbial nucleic acids (Takeda & Akira, 2005). 
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4. Phylogenetic relationship among TLRs 
A sequence similarity search of different human TLRs revealed that TLRs can be subdivided 
into five subfamilies i.e. TLR2, TLR3, TLR4, TLR5 and TLR9 subfamilies. While the TLR3, 
TLR4 and TLR5 are the only respective members of their subfamily, TLR2 subfamily 
comprises of four members viz. TLR1, TLR2, TLR6 and TLR10; TLR9 family has three 
members TLR7, TLR8 and TLR9. Members within a subfamily exhibit high ratio of similar 
sequences than members of other subfamily eg. TLR1 and TLR6 show about 70% similarity 
in their amino acid sequence, identity approaches about 90% in their TIR domains. 
 
 
 
 
Fig. 2. Human TLRs can be divided into five subfamilies- TLR2, TLR3, TLR4, TLR5 and 
TLR9. Division is based on the amino acid sequence similarity. 
5. Ligands of TLRs 
TLRs are able to recognise a wide variety of pathogens and thereafter signal transduction 
commences that leads to mounting of desirable immune response against the pathogen like 
expression of inflammatory cytokines, chemokines, antibacterial peptides, enhanced 
expression of co-stimulatory molecules etc. Generally every TLR recognises more than one 
type of PAMP e.g. TLR4 (first TLR to be discovered in mammals) has the ability to recognise 
a variety of PAMPs diverse in nature, for instance it can recognise LPS from bacteria, taxol 
from plant, different proteins of viral origin, Hsp 60 and 70 from the host cell itself etc. Like 
TLR4 other TLRs are also able to recognise a wide variety of pathogens which is briefly 
summarised in Table 1. 
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TLR  LIGANDS 
 
TLR1 
 
Tri-acyl lipopeptides (bacteria, mycobacteria) 
Soluble factors (Neisseria meningitides) 
TLR2 Lipoprotein/lipopeptides (a variety of pathogens) 
Peptidoglycan (Gram-positive bacteria) 
Lipoteichoic acid (Gram-positive bacteria) 
Lipoarabinomannan (mycobacteria) 
A phenol-soluble modulin (Staphylococcus epidermidis) 
Glycoinositolphospholipids (Trypanosoma Cruzi) 
Glycolipids (Treponema maltophilum) 
Porins (Neisseria) 
Zymosan (fungi) 
Atypical LPS (Leptospira interrogans) 
Atypical LPS (Porphyromonas gingivalis) 
HSP70 (host) 
 
TLR3 Double-stranded RNA (virus) 
 
TLR4 LPS (Gram-negative bacteria) 
Taxol (plant) 
Fusion protein (RSV) 
Envelope proteins (MMTV) 
HSP60 (Chlamydia pneumoniae) 
HSP60 (host) 
HSP70 (host) 
Type III repeat extra domain A of fibronectin (host) 
Oligosaccharides of hyaluronic acid (host) 
Polysaccharide fragments of heparan sulfate (host) 
Fibrinogen (host) 
 
TLR5 Flagellin (bacteria) 
TLR6 Di-acyl lipopeptides (mycoplasma) 
 
TLR7/8 Imidazoquinoline (synthetic compounds) 
Loxoribine (synthetic compounds) 
Bropirimine (synthetic compounds) 
 
TLR9 CpG DNA (bacteria) 
Hemozoin (protozoa) 
 
TLR10           ? 
TLR11 Component of uropathogenic bacteria (bacteria) 
Profilin like molecule (protozoa Toxoplasma gondii) 
 
Table 1. TLRs and their corresponding ligands. 
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6. TLRs bridge innate and adaptive immunity 
TLRs serve as a link between innate and adaptive immunity by induction of dendritic cell 
(DC) maturation and directing T helper responses (Parker et al., 2006). It has been reported 
that stimulation of specific TLRs leads to induction of either IL-10 or IL-12 that results in a 
response biased towards either Th1 or Th2 cytokines. TLR2 mediated response 
preferentially leads to release of Th2 cytokines while TLR4 induces Th1 cytokine release. 
DCs have been reported to express TLRs on their surfaces which respond to different 
microbial antigens differently. Immature DCs have high phagocytic activity but low T cell 
activation potential and these are capable of detecting, capturing and phagocytosing 
pathogens that ultimately leads to activation of TLRs and cytokine release. A signalling 
cascade commences after TLR activation (as described later) which serves as a complex 
differentiation programme for DCs, collectively termed DC maturation. This DC maturation 
is characterised by up-regulation of co-stimulatory molecules such as CD40, CD80, and 
CD86. CD80 and CD86 are the two requisite signals for naïve T cell activation (Banchereau 
& Steiman, 1998; Parker et al., 2006).  
Also, when TLRs on many cell types are stimulated by TLR agonists, bacteria and viruses, it 
leads to the production of type I interferon (IFN-ǂ/ǃ) (Parker et al., 2006). This response is 
popularly attributed to be part of first line of defence against infection and a central 
modulator of adaptive immunity. Proliferation of memory T cells, inhibition of T cell 
apoptosis, enhanced IFN-Ǆ secretion, B-cell isotype switching and differentiation into 
plasma cells and NK cell activation are some of the attributes of IFNs owing to their diverse 
functions in the development of adaptive immunity.  
In addition to up-regulation of CD80/CD86 molecules on DCs and production of type I 
interferon (IFN-ǂ/ǃ) to control T cell activation, another mechanism of T cell activation 
exists in which T cell responses are regulated by CD4+ CD25+ suppressor or regulatory T 
cells (Treg cells). The Treg cells function to induce tolerance in peripheral T cells (both self-
reactive and non-self-reactive T cells), a malfunctioning of these cells leads to autoimmune 
diseases. It has been reported that DCs produce IL-6 in response to TLR activation that is 
critical for T cell activation as it relieves suppression of effector T cells (non-self-reactive T 
cells) by Treg cells (Pasare & Metzitov, 2003). Pasare & Metzitov also report that T cell 
activation occurs even in the absence of IL-6 when Treg cells are removed. This suggests that 
induction of co-stimulatory molecules on DCs is enough for T cell activation in the absence 
of Treg cells. 
7. TLR signalling 
Toll like receptors after recognising PAMPs initiate intracellular signalling that leads to the 
activation of NF-ĸB (Nuclear factor kappa B) or IRF3 (Interferon regulating factor 3) and 
subsequently expression of genes under their control takes place. To induce intracellular 
signal transduction, TLRs either homodimerise or heterodimerise upon interaction with 
PAMPs. Probably there are two pathways regarding TLR signal transduction, MyD88 
(Myeloid Differentiation Factor 88) dependent and MyD88 independent. 
MyD88 dependent signalling pathway is found to be central to all TLRs except TLR3. 
TIRAP (TIR domain containing adaptor protein) is essential for MyD88 dependent 
signalling through TLR2 and 4 as revealed by the studies with TIRAP deficient mice. 
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MyD88 dependent signalling involves a number of molecules which are briefly described 
below. 
MyD88  
It is encoded by MyD88 gene (Muzio et al., 1997; Wesche et al., 1997; Burns et al., 1998). This 
protein is utilised by all TLRs except TLR3 as an adaptor to transmit the signal inside the cell 
resulting in activation of transcription factor NF-ĸB. Data indicates that another protein 
TIRAP also known as MAL (MyD88 adaptor like protein) is required by MyD88 to be 
recruited to TLR2 and TLR4. MyD88 protein has two domains- N terminal death domain 
(DD domain) and C terminal TIR domain. It interacts with the TIR domain of TLR via its C 
terminal TIR domain. MyD88 is also reported to interact with IL-1R, IRAK1, IRAK2, RAC1 
(Ras mediated C3 botulinum toxin1) and many other proteins. 
IRAK 
IRAKs (IL-1R associated protein kinases) are protein kinases that act downstream of MyD88. 
Four IRAKs are identified in mammals- IRAK1, 2, 4 and M (Janssens & Beyaert, 2003). While 
IRAK1 and 4 are expressed in all cell types, IRAK2 shows narrower distribution and IRAK M 
is reported to be only expressed in cells of myeloid origin. IRAKs have an N terminal death 
domain but lack a TIR domain. But a central serine threonine kinase domain is present. IRAK1 
and 4 have intrinsic kinase activity while IRAK2 and M are with no kinase activity. 
TRAF 
TRAFs (TNF receptor associated factors) are proteins having an N terminal coiled coil 
domain known as TRAF-N and a conserved C terminal domain known as TRAF- C (Bradley 
& Pober, 2001). There are six members in the mammalian TRAF family (TRAF1, TRAF2, 
TRAF3, TRAF4, TRAF5 and TRAF6). Binding of TRAF to its interacting proteins require that 
proteins should contain TRAF binding motif of which consensus sequence is identified and 
found to be as Pro-X-Glu-X-X-(aromatic/acidic residue) (Ye et al., 2002). This motif is found 
to present in CD40, IRAK1, IRAK2, IRAK4, TRANCER (TNF related activation induced 
cytokine receptor).  
TAK1 and TABs 
Activation of IKK complex (Inhibitor of NF-KB kinase complex) by TRAF6 requires two 
factors TRIKA1 (TRAF6 regulated IKK activator1) and TRIKA2 (TRAF6 regulated IKK 
activator2). Further studies revealed that TRIKA1 is composed of Ubc13 (Ubiquitin 
conjugating enzyme 13) and Uev1A (Ubiquitin conjugating enzyme variant1) which act as 
ubiquitin conjugating enzyme complex. Polyubiquitination of TRAF6 is done by TRIKA1 
complex with lysine 63 (K63) of ubiquitin. This polyubiquitination directly activates the 
TAK1 in a proteasome independent manner. TRIKA2 is composed of TAK1, TAB1 and 
TAB2. TAK1 (TGF-ǃ activated kinase) belongs to a MAPKKK family of protein kinases 
(Yamaguchi et al., 1995). TABs are TAK1 binding proteins (Shibuya et al., 1996; Takaesu et 
al., 2000). TAB1 acts as co-activator of TAK1 enhancing its kinase activity while TAB2 has an 
adaptor function linking TAK1 to TRAF6. 
NF-ĸB 
NF-ĸB (Nuclear factor kappa B) is a transcription factor that controls the expression of genes 
involved in inflammation, immunity and apoptosis. It was discovered as a transcription 
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factor for the K chains in immunoglobulins. About 100 genes are under the transcriptional 
control of NF-ĸB. It belongs to rel family of proteins. NF-ĸB is an evolutionary conserved 
protein having five members in mammals- p50, p52, RelA/p65, RelB and RelC. All these 
function either as homodimer or heterodimer for e.g. p50 homodimer and p50/p65 
heterodimer. Their ability to regulate and control transcription also differs markedly, for 
instance p65 and Rel-C are most potent transcriptional activators while p50 homodimers 
seem to repress transcription. NF-ĸB is composed of two subunits p50 and p65. It is bound 
to an inhibitory protein IκB via non-covalent interaction which hampers its activity. Studies 
indicate that p50 and p65 dimerise around a 10 base pair region referred to as κB sites. 
Sequence of this site is 5’GGGRNNYYCC3’ where R, Y and N refer to purine, pyrimidine 
and any base respectively.  
7.1 MyD88 dependent signalling pathway 
MyD88 is an adaptor protein that is recruited to the TIR domain of TLR upon its activation 
via C terminal TIR domain. MyD88 also has a death domain at its N terminal end spaced 
with a short linker sequence from its C terminal. MyD88 then recruits IRAK4 (IL-1R 
associated protein kinase 4) at its death domain via its N terminal. IRAK4 has N terminal 
death domain and a central serine/threonine kinase domain that is essentially required for 
its kinase activity and downstream signalling. This recruitment of IRAK4 to MyD88 induces 
conformational changes in IRAK4 that allows the interaction of IRAK1 with it and then 
IRAK4 acts on IRAK1 to phosphorylate it. Also upon activation, IRAK1 starts auto-
phosphorylating itself (Takeda & Akira, 2005). To this assembly, TRAF6 (TNF receptor 
associated factor 6) further associates via phosphorylated IRAK1. TRAF6 acts as a signalling 
mediator for both IL-1R/TLR superfamily and TNF receptor superfamily. Association of 
TRAF6 with phosphorylated IRAK1 leads to the dissociation of both these mediators from 
the assembly and binding to TAK1 (Transforming growth factor ǃ activated kinase), 
TAB1(TAK1 binding protein 1) and TAB2 (TAK1 binding protein 2). TAK1 belongs to 
MAPKKK (Mitogen activated protein kinase kinase kinase) family. TAB1 acts as an activator 
of TAK1 while TAB2 functions as an adaptor molecule linking TAK1 to TRAF6. Recently, 
another TAK1 binding protein, TAB3 came into being and might function similar to TAB2. 
This causes phosphorylation of TAB2 & TAK1 and degradation of IRAK1. This remaining 
complex i.e. TAK1, TAB1, TAB2 and TRAF6 now gets associated with ubiquitin ligase 
UBC13 (Ubiquitin conjugating enzyme 13) and UEV 1A (Ubiquitin conjugating enzyme E2 
variant 1). This leads to activation of TRAF6 which in turn activates TAK1. TAK1 activation 
takes place through linkage of a lysine63 linked polyubiquitin chain via TRAF6-UBC13 
complex where TRAF6 acts as an E3 Ubiquitin ligase (Wang et al., 2001). Activated TAK1 is 
responsible for the phosphorylation of MAPK and IKK complex ( Inhibitor of NF-κB (IκB) 
kinase complex). IKK has three subunits, IKK1 or IKKǂ, IKK2 or IKKǃ and IKKϒ or NEMO 
(NF-κB essential modulator) (Karin & Ben-Neriah, 2000). This kinase complex 
phosphorylates IκB at conserved serine residues in N terminal which mark it for 
ubiquitination and its subsequent degradation via proteasome. Removal of inhibitor from 
NF-κB leads to its activation and translocation from cytosol to nucleus where it binds to NF-
κB binding regions (present in the genes under the control of NF-κB transcriptional 
activation) and induce the transcription of genes responsible for synthesis of effector 
molecules that act against the invading pathogen or PAMPs and lead to their destruction. 
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Fig. 3. Upon stimulation of TLR with suitable PAMP, MyD88 is recruited to TIR domain of 
TLR. IRAK4 then associates with MyD88. This causes IRAK1 to attach with IRAK4 which 
causes its phosphorylation. TRAF6 then joins this complex and thereafter causes IRAK1 to 
dissociate from IRAK4 along with it. Later TRAF6 and IRAK1 bind to TAK1, TAB1 and 
TAB2. Later IRAK1 is degraded and remaining complex joins Ubc13 and Uev1A which 
causes polyubiquitination of TRAF6 and activates TAK1 in a proteasome independent 
manner. Activated TAK1 phosphorylates both MAPK and IKK complex. IKK complex 
phosphorylates IκB that leads to its ubiquitination and then degradation in proteasome. 
Release of IκB from NF-κB activates it which then translocates into the nucleus and causes 
the expression of genes which are under its transcriptional control including genes involved 
in apoptosis, inflammation and immunity.  
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7.2 MyD88 independent signalling pathway 
Studies have revealed that upon stimulation with LPS in MyD88 deficient cells, there is still 
production of NF-κB, although the production is delayed. This leads to the fact that TLR 
signalling can also occur in the absence of MyD88 i.e. independently of MyD88. TLR3 
utilizes MyD88 independent signalling pathway to activate IRF3 that is responsible for the 
up-regulation of interferon (IFN) inducible genes and the production of IFN-ǃ. This MyD88 
independent signalling pathway utilizes another adaptor molecule known as TRIF/TICAM1 
( TIR domain containing adaptor protein inducing IFN-ǃ/ TIR domain containing molecule 
1). TRIF has TRAF6 binding motifs (T6BM) in its N terminal and a TIR domain and RHIM 
(Receptor interacting protein 1 homotypic interaction motif) domain at its C terminal. TRIF 
is the only molecule meant to be involved in signalling through TLR3. Studies with TRIF 
deficient mice showed impaired response in activation of IRF3 and expression of IFN 
inducible genes only with ligands of TLR3 and TLR4 (Hoebe et al.,2003). IRF3, 5 and 7 play 
important roles in expression of IFN inducible genes during viral infection. IRF3 is typically 
required for the expression of genes encoding IFN-ǃ and genes under the control of other 
interferons (Yoneyema et al., 1998). Upon activation of TLR3 with its ligand, TRIF is 
recruited to the TIR domain of TLR3. Then TRIF associates at its N terminus via two 
molecules- TRAF6 and TBK1 (TRAF family member associated NF- κB activator (TANK) 
binding kinase 1). TBK1 is responsible for phosphorylating the IRF3 at its C terminal 
regulatory domain which leads to their dimerization (Sharma et al., 2003). Dimers are then 
able to translocate into the nucleus and associate with co-activators p300 and CBP( cAMP 
responsive element binding protein).This then causes the expression of genes encoding IFN-
ǃ and other TypeI interferons (Taniguchi & Takaoka, 2002). These TypeI interferons via 
JAK-STAT signalling pathway are capable of inducing the expression of IFN inducible genes 
like GARG16 (Glucocorticoid attenuated responsive gene 16), IPG1( Immunoresponsive 
gene1) and CXCL10 etc. Also, IRF7 is produced later in viral infections via interferons whose 
expression is regulated by IRF3. TRAF6, another molecule that associates with TRIF at its N 
terminal is meant to activate NF-κB. TRAF6 binds to N terminal of TRIF via its TRAF-C. 
TRIF has three T6BM with consensus sequence Pro-X-Glu-X-X-(aromatic/acidic residue). 
Also, to the C terminal of TRIF, RIP1 (Receptor interacting protein 1) binds which is 
discovered recently and also found to activate NF- κB (Meylan et al., 2004). Activated NF-κB 
then is able to translocate and causes the expression of genes under its control. It has been 
found that transcriptional activation of IFN-ǃ encoding gene needs both NF-κB and IRF3. 
However, inflammatory cytokine production still remains impaired. 
Search for adaptors containing TIR domain led to the discovery of a new adaptor molecule 
known as TRAM/TICAM2 (TRIF related adaptor molecule/TIR domain containing 
molecule2) (Bin et al., 2003). Studies with TRAM deficient mice revealed that TRAM is 
involved in signalling through TLR4 in a MyD88 independent/TRIF dependent manner 
(Yamamoto et al., 2003). TRAM has a TIR domain in the C terminal and it acts upstream of 
TRIF while mediating TLR4 signalling exclusively. Studies showed that siRNA mediated 
inhibition of TRAM expression causes impairment of IRF3 activation and expression of IFN 
inducible genes only in response to TLR4 ligand, eg. LPS. However, TRAM knockout mice 
shows normal activation of IRF3 and expression of IFN inducible genes in response to TLR3 
activation. Hence, TRAM is only involved in signalling through TLR4 but not TLR3. MyD88 
deficient macrophages when stimulated with LPS show activation of IRF3 and also 
production of NF-κB, although production is delayed. Also, the production of inflammatory 
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cytokines is impaired in these cells. Studies with TRIF and TRAM deficient mice showed 
that for the production of inflammatory cytokines via TLR4, activation of both the signalling 
pathways is required i.e. MyD88 dependent and independent, although the mechanism is 
not clear. However, the production is not affected via MyD88 dependent pathway in 
response to ligands of TLR2, 7 and 9. Another adaptor that is involved in signalling via 
TLR4 is TIRAP/MAL (TIR domain containing adaptor protein/MyD88 adaptor like protein) 
(Horngs et al., 2001). TIRAP deficient mice show impaired production of inflammatory 
cytokines in response to TLR2 and 4 ligands but not to TLR3, 5, 7 and 9 ligands. This 
confirms its role in signalling through TLR2 and 4. TIRAP deficient mice also show IRF3 
activation and production of late phase NF-κB as seen in the studies with MyD88 deficient 
mice. TIRAP has a C terminal TIR domain but it lacks a death domain that is present in 
MyD88. It acts upstream of MyD88. 
LPS signalling through TLR4 is mediated with the help of several other proteins eg. MD-2 is 
a novel protein that mediates the TLR4 signalling in response to LPS. MD2 functions to bind 
LPS and then presents this LPS to TLR4 via physically interacting with it. MD2 is found to 
attach with TLR4 extracellular domain. Also, another protein CD14 is found to facilitate LPS 
signalling via TLR4. CD14 along with LBP (LPS binding protein) binds to LPS (Wright et al., 
1990) and can initiate signalling via transmembrane receptors like TLR4.  
7.2.1 Genes under transcriptional control of NF-κB 
NF-κB is crucial for the expression of genes which are involved in immune responses (both 
innate and adaptive), inflammation, viral infection, stress, cytokine signalling, acute phase 
responses etc. Genes under the regulation of NF-κB have NF-κB binding sites in their 
promoter region. Adhesion molecules like ICAM-1, VCAM-1, E-selectins are expressed as a 
result of NF-κB transcriptional activation. ICAM-1/CD54 (Intercellular adhesion molecule -1) 
is expressed on endothelial and immune system cells. ICAM-1 expression upon required 
stimulus is enhanced via NF-κB activity. ICAM-1 binds to LFA1 (Lymphocyte function-
associated antigen1), a receptor on leukocytes. Leukocytes adhere and then migrate into the 
tissues via ICAM-1 and LFA-1 interaction and carry out the required actions. VCAM-
1(Vascular cell adhesion protein-1) is present in the endothelial cells and function to adhere 
lymphocytes, basophils, monocytes etc. to vascular endothelium. E-selectin/CD62E/ELAM-
1(Endothelial leukocyte adhesion molecule-1) is expressed on vascular endothelium in 
response to TNF-ǂ and IL-1ǃ. It binds to carbohydrate moieties on some leukocytes. Genes 
expressing growth factors are also up-regulated by NF-κB like genes for GM-CSF 
(Granulocyte macrophage colony stimulating factor), M-CSF/CSF1 (Macrophage colony 
stimulating factor/ Colony stimulating factor3) and G-CSF(Granulocyte colony stimulating 
factor/ Colony stimulating factor 3). GM-CSF is a cytokine that stimulates stem cells to 
differentiate into neutrophils, eosinophils, basophils, granulocytes and monocytes. M-CSF is 
also a cytokine that stimulates stem cells to differentiate into macrophages and related cell 
types. G-CSF acts on bone marrow to form more of granulocytes and stem cells. Various 
chemokine genes also show enhanced expression in response to NF-κB like genes for 
Eotaxin, RANTES (Regulated upon activation, normal T cell expressed and secreted), MIP 
1ǂ (Macrophage inflammatory protein 1 ǂ) etc. Eotaxin is a chemokine that recruits 
eosinophils while RANTES is a chemoattractor for T cells, K cells, eosinophils, dendritic 
cells and is also responsible for recruiting leukocytes at inflammatory sites. Several cell 
surface receptor genes are up-regulated eg. CCR5 (C-C chemokine receptor  
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Fig. 4. TLR3 recruits TRIF upon stimulation with its ligand. To N terminal of TRIF, TBK1 
associates which carries out later phosphorylation of IRF3. Upon phosphorylation, IRF3 
forms dimer and translocates into nucleus and causes the expression of genes of IFN-ǃ and 
Type I interferons. Also, to the N terminal of TRIF, TRAF6 binds which activates NF-κB 
which is then able to translocate and causes the transcription of genes under its control. 
Genes encoding IFN-ǃ require activation of both NF-κB and IRF3.  
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Fig. 5. Response to LPS is mediated through TLR4; LPS binds to LBP, and then forms a 
complex with CD14. This complex interacts with MD-2 which is able to interact physically 
with TLR4. Signalling downstream afterwards proceeds either via MyD88 dependant or 
MyD88 independent pathway. In MyD88 dependant pathway, NFĸB is activated which 
induces transcription of several genes including genes of inflammatory cytokines. On the 
other hand, in TIRAP and MyD88 knockout mice, activation of IRF3 and late phase NFĸB 
takes place both of which are able to initiate transcription of the genes under their respective 
control. 
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type 5), CD86, TCR(T cell receptor), MHC class I & II, PAF( Platelet activating factor) 
receptor. Enhanced expression of MHC molecules and TCR means to up-regulate T cell 
activation and hence adaptive immunity. CD80 and CD86 are the major T cell co-
stimulatory molecules. CCR5 is the receptor for RANTES, MIP 1ǂ and 1ǃ. Cytokine IL-1ǃ, 
IL-2, IL-6 and TNFǂ show enhanced expression after NF-κB activation. NF-κB dependent 
stimulation of iNOS promoters also takes place.  
8. TLR signalling is negatively regulated 
Docking of pathogen onto TLRs and their subsequent stimulation induces production of 
inflammatory cytokines such as TNF-a, IL-6 and IL-12. An uncontrolled and excessive 
cytokine production can lead to manifestation of serious autoimmune and inflammatory 
diseases. Hence, to avoid an excessive inflammatory response, organisms have evolved 
mechanisms which make a balance between TLR activation and inactivation. Several 
molecules modulating TLR-mediated responses have been unravelled. Negative regulators 
of TLRs can either be extracellular or intracellular (Arancibia et al., 2007). 
Extracellular regulators comprise of soluble form of TLRs. Soluble form of TLR2, sTLR2, is 
produced by a post-translational modification of the membrane bound TLR2. It is reported 
that if sTLR2 splice variant expression is inhibited, an augmented response to bacterial 
lipopeptide is seen (Lebouder et al., 2003). Alternate splice variant of TLR4 (soluble TLR4), 
sTLR4, is shown to be involved in the inhibition of LPS-mediated TNFǂ production and 
NFĸB activation, blocking MD-2 (a co-receptor of TLR4) recruitment to the TLR4-CD14 
complex. Also, soluble product of TLR5, sTLR5, is seen to be implicated in cellular response 
of flagellin that induces an increased NF-ĸB activation by an unknown cellular mechanism. 
A variety of intracellular molecules (adaptors and kinases) are found to regulate TLR 
signalling. An alternatively spliced variant of MyD88 that lacks the intermediary domain of 
MyD88 (MyD88s) is induced in monocytes upon LPS stimulation. Overexpression of 
MyD88s results in impaired LPS-induced NF-ĸB activation through inhibition of IRAK-4-
mediated IRAK-1 phosphorylation. IRAK-M is another negative regulator of TLR signalling 
cascade and it lacks catalytic kinase activity. IRAK-M inhibits expression of pro-
inflammatory cytokines by preventing IRAK-1/IRAK-4 dissociation from MyD88, hence 
causing inhibition of IRAK-1-TRAF6 complex formation. The fact that IRAK-M plays a 
crucial role in regulating MyD-88 dependant signalling pathway can be established from the 
information that IRAK-M-/- mice overproduce inflammatory cytokines in response to LPS 
and CpG DNA (Arancibia et al., 2007). 
A protein associated with Toll-Like Receptor 4 (PRAT4A) regulates cell surface expression 
of TLR4. PRAT4A is associated with the immature form of TLR4 but not with MD-2 (a TLR4 
co-receptor) or TLR2. PRAT4A knockdown led to the profound defect in LPS responsiveness 
in a cell line expressing TLR4/MD-2, probably due to impaired maturation of TLR4, leading 
to the lack of mature TLR4/MD-2 on the cell surface. PRAT4A is likely to be a component of 
the machinery facilitating TLR4/MD-2 trafficking to the cell surface. Hence, PRAT4A is 
another negative regulator of TLR4. 
SOCS1 and SOCS3 belong to SOCS (Suppressor of cytokine signaling) family of proteins. 
These proteins themselves induced by cytokines, negatively regulate TLR4/NFĸB signalling 
pathways (Gingras et al. 2004). In SOCS 1-/- mice defective induction of LPS tolerance was 
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observed as they were found to be hypersensitive to LPS-endotoxin. In the same manner, 
LPS induced TNF-ǂ production was found to be suppressed in macrophages exposed to IL-
10 and IL-6 isolated from SOCS3-/-(Arancibia et al., 2007). 
PI3K, implicated in TLR signalling, has been found to suppress both MAPKs and NFĸB 
induced by LPS, thereby decreasing TNF-ǂ production (Arancibia et al., 2007). Tollip (Toll 
interacting protein) has also been found to play an inhibitory role in TLR signalling. Tollip 
when in association with TIR domain decreases IRAK-1 phosphorylation upon LPS 
activation. A plausible role of PI3K in regulating inhibitory effects of Tollip has been 
proposed. PI3K does that by interacting with 3’ phosphorylated phosphatidylinositides 
(Arancibia et al., 2007). 
SIGIRR (single immunoglobulin IL-1 receptor-related molecule) and T1/ST2, membrane 
bound proteins adhered to the TIR domain, have also been found to be negative regulators 
of TLR signalling (Takeda & Akira, 2005). Nucleotide oligomerization domain receptor 
(NOD2), a mammalian PRR, too seems to be a negative regulator as NOD2-/- macrophages 
when stimulated by TLR agonists produce significantly higher amount of cytokines but on 
restoration of NOD phenotype, cytokine expression is lowered (Arancibia et al., 2007).  
Activating Transcription Factor-3 (ATF-3) has also been found to negatively regulate TLR-
signalling pathways (Whitmore et al., 2007). It has been observed that different TLR ligands 
(i.e., zymosan for TLR2/3, pIC for TLR3, LPS for TLR4, and CpG-ODN for TLR9) stimulate 
rapid induction of ATF3 in cultured mouse macrophages. It is reported that primary 
macrophages of mice lacking atf3 gene (ATF3-knockout (KO)) show enhanced expression of 
TLR-induced IL-12 and IL-6 when compared to wild type macrophages. In a reporter assay, 
ectopic expression of ATF3 was found to antagonize TLR-stimulated IL-12p40 activation. 
Further, CpG oligodeoxynucleotide, a TLR9 agonist when introduced in ATF3-KO mice 
resulted in enhanced cytokine production from splenocytes. Hence, it can be concluded that 
atf3 deficiency leads to altered pattern of immunological response and ATF-3 is a negative 
regulator of TLR pathways. 
In addition to these, degradation of TLRs (either ubiquitination mediated or lysosomal) is 
also proposed as a mechanism for negatively regulating TLR signaling (Takeda & Akira, 
2005; Wang et. al., 2007). A RING finger protein, Triad3A, has been found to act as an E3 
ubiquitin ligase, ligating ubiquitin molecules onto the TLR4 and TLR9 and enhancing 
their proteolytic degradation. A recent study by Wang et. al. (Wang et. al., 2007) reveals 
another mechanism of negative regulation of TLR4 signalling, by lysosomal degradation 
of TLRs. They propose that Rab7b, a lysosome associated small GTPase negatively 
regulates NF-ĸB and IRF3 signalling pathways in macrophages by promoting lysosomal 
degradation of TLR4 and decreasing the cell surface expression of TLR4. These complex 
mechanisms of negative regulation of TLRs emphasize that it is important for prevention 
of uncontrolled immune activation in the host. 
9. TLRs in various diseases 
9.1 TLRs in nervous system diseases 
TLRs have been considered earlier as receptors expressed solely on antigen presenting cells 
of the immune system i.e. B cells, dendritic cells, monocytes, macrophages etc. and mediate 
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innate immunity. However, with advancement in techniques, it is clear that nearly all cells 
within the body express TLRs, including different brain cell types such as microglial cells, 
astrocytes, oligodendrocytes and neurons within the CNS (Central Nervous System). The 
present section will focus the role of TLRs in these brain cells. 
Microglia 
Microglial cells are bone marrow-derived macrophage-like cells constituting about 10% of 
the adult CNS and mediate neuronal immune interactions under both physiological and 
pathological conditions (Pessac et al., 2001). Microglial cells are the key defence against 
invading pathogens within the CNS, and it is not surprising, therefore, that activation of 
these cells either by a single type of ligand or a combination of ligands, leads to secretion of 
a milieu of cytokines and chemokines. It is now well known that microglial cells express 
wide receptors of TLRs in addition to their adapter proteins, required for functional 
downstream TLR signalling. Recent studies showed that TLR1-9 are expressed in microglia 
(Jack et al., 2005). Upon activation, TLR mRNA and protein expression is increased in 
microglia. As a result of TLR activation, these cells secrete higher amounts of pro-
inflammatory cytokines and hence show pathogen specific responses. TLR signalling in 
microglia may also have a role in cell death and survival following inflammatory activation 
which suggests a paradigm in which auto-regulation of the innate immune system exists in 
the CNS which helps to prevent excessive inflammation during pathogen infection (Jack et 
al., 2007; Tanaka et al., 2008; Okun et al., 2009). 
Astrocytes 
Astrocytes are characteristic star-shaped glial cells in the brain and spinal cord and perform 
many functions, including biochemical support to endothelial cells that form the blood–brain 
barrier provision of nutrients to the nervous tissue, maintenance of extracellular ion balance, 
and a role in the repair and scarring process of the brain and spinal cord following traumatic 
injuries. Similar to microglial cells, astrocytes exhibit a wide expression of TLRs. Astrocytes 
express robust TLR 3 with low expression of TLR 1, TLR4, TLR5 and TLR9, and with rare 
expression of TLR2, TLR6, TLR7, TLR8 and TLR10. Several cytokines and chemokines are 
reportedly produced following TLR activation in astrocytes. TLR 3 signalling induces 
strongest pro-inflammation polarizing response by secreting increased levels of IL-12, TNF-
alpha, IL-6, CXCL-10, IFN-beta and IL-10 (Jack et al., 2005). Both cytokines and TLR agonists 
induce expression of chemokine ligands i.e. CCL2, CCL3, CCL5, ICAM-1 and vascular cell 
adhesion molecule-1 (VCAM-1) (Carpentier et al., 2005 ; Okun et al., 2009).  
Oligodendrocytes 
Oligodendrocytes are a type of neuroglia and function as an insulation of axons in the CNS. 
As compared to other CNS cell types, very little is known regarding the expression and 
function of TLRs in oligodendrocytes. The first report on TLRs in these cells has shown the 
predominant expression of TLR2 and 3 as evidenced by promotion of survival, 
differentiation, and myelin-like membrane formation and induction of apoptosis by TLR2 
agonist, zymosan and TLR3 agonist, poly-I:C respectively (Bsibsi et al., 2002). While the 
exact role of TLR2 in oligodendrocytes is unknown, in vivo evidences suggest that activation 
of this receptor is involved in CNS repair by enhancing myelination of neurons in the CNS 
and damage repair after spinal cord injury (Okun et al., 2009).  
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Neurons 
Neurons are the core components of the CNS which processes and transmits information by 
electrical and chemical signalling. During the past few years, evidence for the neuronal 
expression of TLRs has increased, suggesting a role for this receptor family in neurons 
during physiological as well as pathological conditions. The expression of the mRNA for 
TLRs1-9 as well as protein levels of TLR 2, 3 and 4 has been shown in vivo following 
infection in a parasitic model of neurocysticercosis (Tang et al., 2007). Studies provide 
evidence that neurons from both the central and peripheral nervous systems express TLR3 
and that it is concentrated at the growth cones of neurons. In addition to TLR expression in 
brain diseases, it is known that neuronal TLR activation plays a role in development. It has 
been reported recently that treatment of cultured embryonic cortical neurospheres with a 
TLR3 ligand significantly reduced proliferating (BrdU-labeled) cells and neurosphere 
formation, whereas neural progenitor cells (NPC) from TLR3-deficient embryos formed 
greater numbers of neurospheres compared to neurospheres from wild-type embryos (Okun 
et al., 2009). A distinct difference is apparent between the effects of TLR activation in 
differentiated neurons and neuronal progenitor cells. Apart from the classical TLR ligands 
such as LPS (TLR4) or Pam3CSK4 (TLR2), it is considered that neuronal TLRs respond to 
endogenous ligands but not to pathogen-derived ligands (Okun et al., 2009).  
9.1.1 TLRs in neurodegeneration 
TLRs generally respond against invading pathogens, however, they can also be activated in 
the absence of microbial infection and regulate neurogenesis. Studies examining 
inflammatory markers in normal brain aging have also suggested a dynamic regulation of 
TLRs and hence, showed its participation in aging and age-related disease. Despite the 
emerging role of TLRs in stokes, AD (Alzheimer’s disease) and MS (Multiple sclerosis), very 
little is known regarding the function of these receptors in other neurodegenerative 
disorders. In this context, the role of TLRs in brain diseases such as, Alzheimer’s disease, 
multiple sclerosis and other neurodegenerative conditions is discussed herewith. 
9.1.2 TLRs in Alzheimer’s disease 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized by 
gradual onset and advancement of memory loss and other cognitive deficits. Definitive 
diagnosis of AD is based on the presence of extracellular amyloid plaques comprised of 
neurotoxic amyloid ǃ-peptide (Aǃ) which is generated by proteolysis of the ǃ-amyloid 
precursor protein (APP), and intracellular neurofibrillary tangles composed of hyper-
phosphorylated insoluble forms of tau protein. TLR expression is up-regulated and 
increased in the AD brain. A screening of TLRs in murine models of AD revealed an up-
regulation of TLR2 and TLR7 transcription levels compared to wild-type controls. Further, 
multiple TLR genes (1-8) are expressed in microglia in post-mortem tissue from AD patients, 
with varying levels of expression. The increased expression of TLRs in AD positions them as 
potential players in neurodegenerative mechanisms and disease progression. The TLR4 
gene has emerged as a candidate susceptibility gene for AD. A common missense 
polymorphism occurs at the TLR4 gene locus resulting from an adenine to guanine 
substitution 896 nucleotides downstream of the transcription start site. This substitution 
causes the replacement of glycine for aspartic acid at amino acid 299 (Asp299Gly), and alters 
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the structure of the extracellular domain of TLR4. This mutation attenuates TLR4 signalling 
in response to LPS and diminishes the ability to induce inflammation (Arbour et al, 2000). In 
AD brain, activated glia expressing high levels of TLR4 and TLR2 surround Aǃ plaques. The 
close association between Aǃ plaques and reactive astrocytes and microglia has led to the 
assertion that these cells contribute to plaque formation (Walter et al., 2007). TLR4 
expression increases during exposure to Aǃ and the lipid peroxidation product 4-hydroxy-
nonenal (HNE). Further, c-Jun N-terminal kinases (JNK) and caspase-3 activity levels are 
augmented in neurons exposed to Aǃ and HNE. Selective elimination of TLR4 function 
significantly suppresses the abilities of Aǃ and HNE to induce activation of JNK and 
caspase-3 (Tang et al., 2007) suggesting that TLR4 expression increases neuronal 
vulnerability to Aǃ-induced damage (Okun et al., 2009). Neurons expressing TLR4 have 
increased sensitivity to Aǃ and are vulnerable to degeneration in AD. In addition to 
epidemiological studies that suggest mutations in TLR4 lead to decreased susceptibility to 
neurodegeneration, several data indicate that activation of TLR4 is required for clearance of 
Aǃ in AD. In addition to TLR4, activation of other TLRs may also contribute to Aǃ clearance. 
Whereas TLRs are activated by exogenous pathogens, mounting evidence indicates that Aǃ 
itself activates TLRs and mediates microglial activation. At present, it still remains to be 
determined if the activation of TLRs by Aǃ contributes to and/or inhibits AD progression. 
Contrasting data exist on the precise role of TLRs in Aǃ deposition. Therefore, there may be 
a balance of TLR activation in which mild activation is beneficial, promoting Aǃ uptake and 
breakdown. However, excessive activation of TLRs on microglia may lead to the 
accumulation of cytotoxic compounds such as reactive oxygen species, cytokines, 
complements and proteases causing damage and eventual neuronal loss. TLR signalling 
pathways are a potential therapeutic target in AD; however more work remains to delineate 
the complex interaction of TLRs in Aǃ deposition and clearance and its precise role in AD 
development (Okun et al., 2009; Akiyama et al., 2000). 
9.1.3 TLRs in Multiple Sclerosis 
Multiple Sclerosis (MS) is a chronic inflammatory and demyelinating disease of the CNS 
and characterized by recurrent neurological dysfunction. It is believed to be an immune-
mediated disease in which auto-reactive T cells enter the CNS and drive a pro-inflammatory 
reaction resulting in tissue injury after infection. There is a marked increase in TLR 
expression in multiple sclerosis lesions. Microglial cells from MS patients express TLRs 1-8, 
while, healthy white matter from patients does not contain TLRs. Examination of TLR3 and 
TLR4 localization revealed that early active MS lesions are associated with vesicular 
localization of TLR3 and TLR4 within microglia, located near blood vessels at the outer 
edges of lesions. In contrast, late active lesions also contain astrocytes bearing surface TLR3 
and TLR4. This suggests that early lesions are characterized by microglia infiltration, while 
astrocytes are also active in later MS lesions. Researchers showed that TLR expression is up-
regulated in the brain and spinal cord in animal models of MS. The exact role and 
mechanism of TLRs and its activation in these lesions is still unclear. One hypothesis asserts 
that in response to pro-inflammatory cytokines, microglial cells are capable of serving as 
antigen-presenting cells which can activate CD4+ T cells and facilitate neuroinflammation. 
Therefore, TLR activation may be an essential step in converting microglia to antigen 
presenting cells and facilitate T cell infiltration of MS lesions. Alternatively, TLRs may 
induce production of pro-inflammatory cytokines and thereby inflict damage. It can also 
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happen that endogenous ligands like ganglioside and sialic acid containing 
glycosphingolipids released from apoptotic neurons may bind to TLR4 present on microglia 
and activate it resulting in either neurodegeneration by releasing pro-inflammatory 
molecules or provide neuroprotection by attracting oligodendrocyte progenitor cells to 
lesion sites in MS to promote remyelination. Although TLRs often recognize pathogen-
associated molecular patterns and protect the body from invasion of microbial pathogens, 
the expression of TLRs within multiple sclerosis suggests novel roles for these receptors in 
mediating neurological disease and hence can be used as a biomarker of the 
neurodegenerative disorders (Okun et al., 2009). Moreover, it is important to determine the 
precise role of distinct TLRs in Aǃ recognition and clearance, and the activation of glial cells. 
This may open a window of hope (Arroyo et al, 2011). 
9.1.4 Therapeutic approaches 
TLRs are not only activated in response to microbial infection, but are critically involved in 
mediating neurological dysfunction. The extensive involvement of TLRs in 
neurodegenerative disorders provides wide opportunity for promoting and inhibiting their 
signalling to intervene the progression of the disease. However, it may be difficult to 
achieve the correct balance and appropriate timing of such interventions. There is huge 
variation in the TLR expression and hence the modifications will be varied across different 
disorders and there may exist variability within patients of the same disease. Proper TLR 
targeting will require extensive understanding of the pathways, mechanism activated, cell-
specific responses and the course of disease progression. Both human and animal studies 
implicating TLRs in neural degeneration suggest direct modulation of TLR signalling as an 
ideal therapy. Specific strategies are necessary to circumvent this barrier and allow 
administration of TLR treatments to the CNS. Targeting TLRs in neurological disease will 
not be without difficulties. One potential obstacle to targeting TLR signalling in disease is 
that virtually all cells in the body express TLRs. If chronic administration of TLR agonists is 
necessary, it may result in overstimulation of the immune system, which limits dosage 
capability as well as frequency of application. CNS- specific isoforms of TLR agonists which 
possess high selectivity could prevent such overstimulation of peripheral immune 
responses. In addition, partial agonists may be useful in preventing overstimulation of TLRs 
in the same tissues. Another potential hurdle to TLR- directed therapeutics is cross-talk 
between receptor subtypes. Alternatively, specific TLR activation can induce tolerance to 
stimulation for other TLRs sharing same cascade. Therefore, the consequences of targeted 
TLR stimulation on similar signalling pathways must be carefully considered while 
adapting the therapeutic approaches (Okun et al., 2009).  
9.2 TLRs in cancer and anti-cancer immunotherapy 
Tumour cells in order to survive try to modulate their microenvironment by providing 
signals for uncontrolled growth, anti-apoptosis, angiogenesis and metastasis. Despite all 
these efforts tumour cells get noticed by the immune system which treat cancer cells as 
foreign. The studies have shown that tumour cells have devised sets of strategies to escape 
the surveillance by immune system. TLRs were earlier thought associated only with 
immune cells but recent findings have suggested that tumour cells too have TLRs on their 
surface and may play important role in tumour growth and immune surveillance escape. 
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The tumour cells are able to escape the immune surveillance probably by inhibitory 
cytokines, inflammatory factors, proteinases, and other small molecules such as nitric oxide, 
IL-6 and IL-12. These molecules in conjugation with TLRs may play role in development of 
cancer by providing resistance to tumour cells to apoptosis and immune surveillance. It has 
been seen that upon activation of TLR4, level of X-linked inhibitor of apoptosis and 
phosphorylated Akt (Protein Kinase B, PKB)  are increased. Apoptosis inhibition has been 
seen as the case also in lymphoma and lung cancer cells. Previous studies have given 
evidence in support of LPS as tumour growth promoter through the NF-ĸB resulting in up-
regulation of iNOS and MMP2 and the ǃ1 integrin subunit (Harmey et al, 2002; Wang et al, 
2003). Apart from microbial origin ligands for TLRs, the source of endogenous ligands 
which may promote tumour growth is not clear. The answer to the endogenous source of 
ligands may not only provide some insight to tumour growth but may also help to 
understand autoimmune diseases. It has been proposed that the TLR-4-MyD88 signalling 
pathway may be a risk factor for developing cancer and may represent a novel target for the 
development of bio-modulators. Heat shock proteins such as Hsp60, Hsp70 and Hsp90 may 
induce the production of pro-inflammatory cytokines such as TNF-ǂ, IL-1, IL-6 and IL-12, 
release of NO and chemokines by monocytes, macrophages and dendritic cells (Neill., 2008; 
Asea et al., 2000; Kol et al., 2000; Singh-Jasuja et al., 2000) . There are strong possibilities of 
Hsp60, Hsp70 and Hsp90 being putative endogenous ligands for TLR4. Ulcerative colitis, a 
chronic inflammatory disease of the colon may put an individual at risk of colorectal 
carcinoma. Chronic hepatitis and cirrhosis, pose a risk for the development of hepatocellular 
carcinoma. Research in the past few years have given strong evidence that an inflammatory 
profile of cytokines and chemokines persisting at a particular site would lead to the 
development of a chronic disease. The innate immune system may give in to the promotion 
of tumour growth through inflammation-dependent mechanisms. Recognition of molecules 
either of viral or bacterial origin bearing molecular signature or pattern by TLRs on immune 
cells may induce an inflammatory response associated with tumour promotion. It has been 
observed that bacterial infection post-surgery may promote metastasis of previously 
dormant tumour, and LPS have implicated in leading to this situation (Hsu et al, 2011). The 
MyD88-independent TLR signalling involves the activation of the late phase of NF-ĸB in 
addition to the activation of IFN regulatory factor 3, which ultimately leads to the 
production of type I IFN (IFN a/h), IFN-inducible gene products, and an immune 
regulatory response. Activated TLRs on the surface of tumour cells not only promote their 
own proliferation but also help to build resistance to apoptosis. Further, rouge TLRs may 
enhance tumour cell invasion and metastasis by regulating metalloproteinases and 
integrins. Moreover, the control of TLRs may also lie beyond the traditional boundaries of 
protein molecules into world of miRNA, and their role is still being uncovered. In fact, the 
discovery of miRNAs has indeed brought a paradigm shift in our understanding towards 
the eukaryotic gene regulation. Their uniqueness lies in the fact that these molecules show 
cell or tissue specific expression. In principle, the miRNAs fine tune the gene expression, 
and similar to the classical oncogenes and tumour suppressor genes, miRNA may play part 
in promotion or suppression of malignancies. They act mainly by inhibiting the translation 
or by promoting the degradation of mRNA. For example, miRNAs like miR-146, which 
targets two proteins involved in TLR signalling, TRAF6 and IRAK1, negatively regulates 
mRNAs of both TRAF6 and IRAK1 proteins whereas its own level gets up-regulated in 
response to LPS. Another miRNA, miR-155 targets Src domain containing inositol 5-
phophate 1(SHIP-1) and negatively regulates NF-ĸB signalling. Owing to their role of fine 
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tuner of gene expression pattern, the administration of single miRNA may affect the 
expression pattern of the target gene. Despite some apprehensions over the safety and 
efficacy of miRNA based therapies, a judicial extrapolation to TLR regulated miRNAs may 
provide some therapeutic solution. Also the role of innate immune system in cancer 
development is being looked into more seriously. 
TLRs, tumour cells and Treg cells have been linked. TLR agonists can induce differentiation, 
proliferation or activation of Treg cells. Several TLR agonists such as Streptococcal agent 
OK-432, double stranded RNA and CpG DNA have anti-tumour activity (Chen & 
Oppenheim, 2009). TLR agonists overcome tolerance to self-antigens or tumour-antigens by 
directly or indirectly relieving suppression of effector T cells by Treg cells. A TLR2 agonist 
has been reported to transiently suppress FoxP3 (a member of forkhead/winged helix 
family of transcription factors and a master regulator of Treg development) expression and 
render resistance to suppression by Treg cells of CD4+CD25+ effector T cells. Treg cells 
express TLR4, 5, 7 and 8 in mice. It has been reported that transfer of Treg cells enhanced 
tumour growth in mice but it was reversed upon stimulation of Treg cells with a TLR8 
ligand. Administration of LPS also abrogates Treg activity reveals latent anti-tumour 
immunity ((Chen & Oppenheim, 2009). The biggest problem in using TLRs as anti-cancer 
targets lies in the fact that many cancer patients have very low immunity because of anti-
cancer therapy side effect, thus it becomes very difficult to get innate immune response. The 
quest to arrive at a point where innate immune system’s stimulatory compounds are used 
along with anticancer agents may bear some fruit. The TLR3 has been shown to be receptor 
for viral dsRNA, and also seems to be potentially promising in anti-cancer therapy. Reports 
have shown that cancer cells themselves express TLR3 in vivo and agonist ploy (I:C) is 
activating the signalling pathway leading to the anticancer effects (Elizabeth et al., 2010; 
O'Neill et al., 2011). Hence, this complex relationship of tumour cells and TLRs seems to be 
crucial to determine the balance between beneficial and pathological roles of TLRs. 
9.3 TLRs in asthma and allergy 
Lungs are continuously exposed to microbial pathogens because of their constant 
relationship with the surrounding environment. Therefore, innate immune response in 
lungs to eliminate the pathogen requires expression of TLRs which would be activated upon 
pathogen exposure and subsequently commencing in signalling cascade. This signalling 
culminates in the elevated expression of IL-1-ǃ, TNF-ǂ, IL-12, and IFN-Ǆ. The nature and 
intensity of response is regulated by the display of polarized cytokine profiles, either Th1 or 
Th2. Th2 cytokines are reported to play a crucial role in initiation and perpetuation of 
allergy and asthma (Bauer et al., 2007). Exposure to low doses of LPS results in Th2 biased 
response leading to onset of allergic response. On the contrary, high doses of LPS show 
protective effect. This is confirmed by the studies revealing an inverse relationship between 
allergy and asthma and early childhood exposure to rural farm environment. Although the 
exact mechanistic pathway is yet to be explored, but it becomes quite evident that LPS-TLR4 
complex can either protect or aggravate the severity of asthma, depending on the timing of 
the LPS exposure. This is supported by “hygiene hypothesis” that favours that development 
of asthma and allergies is executed by the reduction in microbial exposure in early 
childhood and decrease in naturally occurring infections. Asthma and allergies are found to 
be less prevalent among individuals brought up in rural farm areas in their childhood 
(Gehring et al., 2002). Such early exposure to farms and barns or early exposure to microbes 
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and microbial components is attributed to the protection rendered in development of 
allergies in later life. This might be because of the induction of regulatory T cells that down-
regulate the adaptive immune responses. 
Apart from the role of TLR4 in allergies, recently it has been reported that TLR2 too 
modulates the development of allergic disease (Bauer et al., 2007). Studies conducted on 
children of farmers of Germany who have decreased risk of developing allergies were found 
to have augmented expression of TLR2 mRNA. The presence of asthma and allergies in the 
children of farmers was co-related with the genetic variation in TLR2. It was found that 
asthma and atopy were less prevalent in the children carrying T allele in TLR2/-16934 (Chen 
et al., 2007).  
9.3.1 TLRs, regulatory T cells and allergy 
A few studies recently have sparked widespread interest in the regulation of allergy as they 
claim that control of allergy is not only restricted to Th1/Th2 bias but other mechanisms as 
well are responsible for controlling inflammatory response and regulatory T cells (Treg 
cells) play a pivotal role in this regulation (Akbari et al., 2002). TLRs are expressed on Treg 
cells (Bauer et al., 2007). A study shows that in adults allergic to pollen, a significant 
reduction in the number of Treg cells and their capacity to restrain allergic response occurs 
when compared to healthy controls. Another finding supports that Treg cells can block 
allergic responses by demonstrating that activation of TLR4 expressed on the CD4+CD25+ 
subset of Treg cells in response to high doses of LPS may prevent activation of pathogenic T 
effector cells and airway inflammation and hyper-reactivity can be overcome by CD4+CD25+ 
Treg cell function in IL-10 dependant manner (Chen et al., 2007). Recently, a report 
elaborates a link between TLR2 and Treg cells as well because in TLR2 mice, CD4+CD25+ 
Treg cell subset was found to be significantly reduced when compared to wild type mice 
(Sutmuller et al., 2006). 
9.3.2 Therapeutic potential of TLR ligands in allergy 
The discovery that TLR signalling culminates in the activation of DCs leading to 
increased Th1 bias can also be applied in the treatment of allergic diseases. Particularly, 
TLR9 stimulation by un-methylated CpG-motif that promotes a Th1 response has been 
explored as potential treatment for atopic diseases like asthma and allergic rhinitis 
(Horner et al., 2001). In mice sensitized with allergen, CpG administration has been 
shown to inhibit the development of airway hyper-responsiveness and eosinophilia. It 
has also been demonstrated that CpG-DNA when conjugated to allergen offer a new 
anti-allergic strategy in which the complexes so formed show a more promising result 
by augmenting the immunotherapeutic effect when compared CpG-DNA given alone or 
CpG-DNA given mixed to allergen (Tighe et al., 2000; Horner et al., 2001). These studies 
encourage usage of selectively targeted allergen TLR-fusion proteins for manipulating 
and eliciting specific immune responses and studies are also suggestive that CpG-DNA 
might be a valuable and potent agent for treatment of allergies. Interestingly, 
imidazoquinoline resiquimod (R-848), a ligand for TLR8 has the potential to revert Th2 
allergic response to Th1 because of its exceptional capability to induce Th1 response 
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(Hemmi et al., 2002). Hence, ligands like imidazoquinoline resiquimod too can be 
therapeutic targets for allergic reactions. 
9.4 TLRs in autoimmune and inflammatory diseases 
9.4.1 Systemic Lupus Erythematosus (SLE) 
SLE is an autoimmune disorder in which antibodies are directed against a range of self-
antigens. Out of these, autoantibodies to nuclear antigens are of keen importance to the 
clinical diagnosis of SLE. Nuclear antigens include dsDNA, ssDNA, nucleolar RNA, 
histone proteins and others. Emerging researches have revealed the involvement of TLRs 
in the progression of autoimmune diseases like SLE, rheumatoid arthritis, diabetes 
mellitus etc. TLR7 and TLR9 are of particular interest in the studies of SLE which are 
located in the endosomal compartments (Anders, 2005; Christensen et al., 2005). It has 
been seen that unregulated or misregulated activation of TLRs can lead to an autoimmune 
phenotypic appearance. Nucleic acids which are usually not immunogenic are not able to 
induce an immune response, but these can become immunogenic via several chemical 
modifications like hypo-methylation, increased oxidation and high CpG content. Immune 
complexes having DNA or RNA which are formed as a consequence of necrosis thus are 
capable of activating TLRs. It has been reported that DNA found in immune complexes 
has 5-6 times more of CpG content and is hypo-methylated in SLE patients. Release of 
autoantibodies and inflammatory cytokines which are responsible for chronic 
inflammation (Christensen et al., 2007; Savarese et al., 2008) can be traced to the improper 
activation of TLR7. In SLE patients, levels of IFNǂ and TypeI interferons are excessively 
high and it is found that higher levels of IFNǂ are beneficiary to the disease progression. 
Nowadays, TLR signalling pathways are directed for therapeutic intervention. Various 
key molecules of TLR7 and TLR9 signalling pathways are targeted to block downstream 
signalling and hence the effector responses. Molecules targeted are MyD88, TRAF6, 
IRAK1 & 4. Other approaches are monoclonal antibodies directed against IFNǂ. Also 
immunoregulatory DNA sequences (IRS) bind to TLRs and block their activation. Hence, 
these can be used as effective strategies in reduction of SLE progression molecules. 
Research for absolute treatment is still in its early stages. 
9.4.2 Rheumatoid Arthiritis (RA)  
 RA is an autoimmune disorder which affects the joints most severely. RA is caused due to 
generation of autoantibodies against the Fc region of IgG. Usually these autoantibodies are 
of IgM type and referred to as rheumatoid factors. Recent studies have revealed that TLRs 
play a significant role in the development of RA. TLR2 & 4 seems to play a crucial role in 
RA. TLR2 & 4 over expression is found in the blood monocytes, synovial fluid macrophages 
and fibroblasts in RA (Iwahashi et al., 2004). Patients with RA are found to have presence of 
TLR ligands in the joints synovial fluid. These ligands can be endogenous (Heat shock 
proteins, HMGB1, hyaluronan etc) (Huang et al., 2009) or can be exogenous like 
peptidoglycan. It has been seen that MyD88 and TLR2/4 deficient mice show reduced 
severity of RA. Currently various approaches are investigated to treat RA effectively. TLR 
antagonists and various TLR signalling molecules are targeted as a promising agent for 
treating RA.  
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9.4.3 Inflammatory Bowel Disease (IBD) 
TLR2, TLR4 and TLR5 have been found to play a role in the pathogenesis of IBD. IBD 
comprises of Crohn’s disease (CD) and ulcerative colitis (UC). Elevated expression of TLR4 
is seen in the colonic tissue of UC and CD patients (Cairo & Podolsky, 2000), but TLR2 is 
found to be highly expressed in mouse manifested with colitis (Singh et al., 2005). This 
shows that IBD may be a consequential result of mutations and dysregulation in TLRs. 
Another family of PRRs, nucleotide binding oligomerization domain proteins (Nod) have 
been reported to contribute to IBD pathogenesis in conjunction with TLRs (Chen et al., 
2007). Polymorphism in Nod2 is attributed to the development of CD. 
9.4.4 Psoriasis 
Psoriasis is a dermatological disorder of chronic autoimmune inflammatory nature. 
Expression of TLR2, TLR5 and TLR1 is altered in psoriatic individuals when compared to 
normal individuals (Chen et al., 2007). TLR2 is found to be highly expressed in the upper 
epidermis in contrast to normal skin where TLR2 is expressed in basal keratinocytes. Basal 
keratinocytes of the lesions also show reduced expression of TLR5 (Baker et al., 2003) and an 
enhanced and diffused expression of TLR1 when compared to normal skin (Curry et al., 
2003). One of the mechanistic explanations of inflammatory response to psoriasis can be that 
the DNA released from keratinocytes in psoriatic skin binds to antimicrobial peptide 
cathelicidin LL37 thus mimicking bacterial DNA and triggers TLR expression on surface of 
immune cell/dendrocytes to activate NF-kB which controls the inflammation. 
9.5 TLRs in infectious diseases 
Apart from inflammatory and immune diseases associated with TLRs, TLRs are vital players 
in infectious diseases as well. One of these is Mycobacterium tuberculosis infection in which 
TLR2, TLR4 and TLR9 have been found to play some role. At an early stage of infection 
TLR2- and TLR4-knockout mice showed an increased susceptibility to the bacteria but it 
subsided at the later stage of infection (Tjarnlund, 2006). It has also been reported that 
absence of TLR2 in mice leads to aggravated inflammatory response (Drennan et al., 2004). 
A study reports that mice double deficient in TLR9 and TLR2 are highly susceptible to 
mycobacterial infection, however, single knockouts in either TLR2 or TLR9 did not show 
this phenomenon (Bafica et al., 2005). Another mycobacterial species, Mycobacterium leprae, 
results in various clinical manifestations associated with host immune response (Chen et al., 
2007). TLR1 and TLR2 have been found to be highly expressed in patients with tuberculoid 
lesions whereas lepromatous lesions lack these TLRs indicating their role in the progression 
of tuberculoid form of the disease (Krutzik et al., 2003). 
Altered expression of TLR4, TLR5 and TLR9 has been observed in Helicobacter pylori 
infection (Chen et al., 2007). TLR4 and MD-2 have been found to be expressed at 
significantly higher levels in gastric mucosa. This indicates the possible role of TLR4/MD-
2 complex in host response to H. pylori derived LPS (Ishihara et al., 2004). Interestingly, 
TLR5 and TLR9 are located on both apical surface and basolateral surface but during H. 
pylori infection, these TLRs are not found to be expressed at the apical surface 
(Schmausser et al., 2005). TLR adaptor protein, MyD88, is found to be crucial in eliciting a 
protective host innate response against Cryptococcus neoformans and Legionella pneumophila 
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infections (Archer et al., 2006; Yauch et al., 2004). The response is generated via activation 
of TLR2. Also Chlamydia pneumonia infection is prevented by TLR2 and TLR4 expression 
(Rodriguez et al., 2006).  
Lyme disease, caused by infection by spirochete Borrelia is also associated with TLRs. Outer 
surface protein A lipoprotein (OspA) is an antigen belonging to Borrelia burgdorferi that 
when docks onto TLR2 and TLR6 culminates in the induction of NFĸB in human dermal 
endothelial cells (HMEC) (Bulut et al., 2001). TLR2/1heterodimerization is essential for the 
macrophages to recognize OspA and initiate desirable immune response against B. 
Burgdorferi (Chen et al., 2007). Absence of chemokine receptor XCR2 results in decreased 
inflammation which is considered as a novel therapeutic target for lyme disease. 
Role of TLRs in viral disease progression is not yet completely elucidated, however, TLR3, 
TLR7, TLR8 and TLR9 have been associated with viral sensing (Kanwar et al., 2011). TLR3 
and TLR9 have been conferred the foremost place in generating viral immunity. TLR3 and 
TLR9 recognize viral double stranded RNA and non-methylated CpG di-nucleotides (both 
of viral and bacterial origin) respectively. TLR7 and TLR8 too leave their signature in viral 
immunity by initiating IFN–ǂ and IFN-ǃ production in DCs and monocytes through IRAK-4 
TLR adaptor (Kanwar et al., 2011). Role of TLR3 has been of prime importance in the 
immune response of lung epithelial cells to Influenza A virus (IAV). Influenza infection 
causes enhanced pulmonary expression of TLR3 in mice. However, IAV-infected TLR3-/- 
mice exhibited significantly reduced levels of inflammatory mediators and lower number of 
CD8+ T lymphocytes in broncho-alveolar space (Le Goffic et al., 2006). Therefore, it can be 
concluded that TLR3-IAV interaction renders the body protected against debilitating host 
inflammatory response. 
10. TLRs as adjuvant vaccines and their role in immune stimulation 
Adjuvant is an agent that may stimulate the immune system and increase the response to an 
antigen or a vaccine without showing any antigenic property of its own. Adjuvants are used 
to augment the effect of a particular vaccine by putting in action the innate and then 
adaptive immune system in action so that the response to a vaccine is more vigorous. 
Adjuvants mimic molecules of bacterial or viral origin which are conserved and bear 
molecular signatures called PAMPs or pattern in terms of conservation. These pattern 
bearing molecules act as a ligand for toll like receptors (TLRs). When TLRs come in contact 
with their appropriate ligands, the receptor-ligand complex gives rise to innate immune 
response which in turn activates adaptive immune system. Since the distribution of TLRs is 
not limited to the innate cells such as DCs, macrophages, natural killer cells, but are also 
found on B cells, T cells, and other non-immune cells such as epithelial, endothelial and 
fibroblast, the importance of giving adjuvant based vaccines can be gauged from the fact 
that ligands will be able to elicit strong immune response from innate to adaptive immunity. 
The adjuvant simply mimics natural infection, which in turn first puts the innate then 
adaptive immune system on, subsequently the purpose of generation of memory cells 
against the desired target is achieved (Kaisho & Akira, 2002).  
The role of TLRs as adjuvant receptors may be exploited to control the TLR signalling using 
immunity modulating reagents which may be used against the pathogens, autoimmune 
diseases, inflammation and cancers. Since TLRs are crucial in recognition of viral and 
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bacterial pathogens, current treatment aims at activating these receptors, generation of pro-
inflammatory response and finally destruction of these pathogens. Ribavarin in combination 
with IFNǂ and resiquimod are currently being used as antiviral drugs. But these molecules 
have their own sets of limitations in terms of side effects. Agonist molecules like ANA773 
and IMO-2125 have shown promising results with their respective receptors TLR7 and 
TLR9. TLR agonists have also been supplemented to boost immune responses to cancer 
vaccines. TLR7 imidazoquinoline ligand 3M-019 has been found to be a potent adjuvant for 
pure protein prototype vaccines (Johnston et al., 2007). TLR2 agonist SMP-105 has been 
approved for the bladder cancer treatment. The compound has shown strong adjuvant and 
antitumor activities. In experimental model, SM-105 has shown anti-tumour property. Thus 
TLRs as adjuvant receptors may open up new avenues of medical treatments. MPL has been 
approved in Europe as adjuvant vaccine. This molecule is a component of the hepatitis B 
vaccine and papillomavirus virus vaccine. It act as a ligand to TLR4 and activates the 
TRAM/TRIF pathway leading to the induction of IFNǃ and regulation of CD80/86. MGN-
1703 and MGN-1706 are double stem loop, non-coding DNA based adjuvants which ligate 
with TLR9 are being developed as anticancer agents. Another vaccine adjuvant, VAX-102, 
which acts as TLR5 agonist is also under trial to treat the viral infections (Elizabeth., 2010). 
This adjuvant vaccine if successful will provide protection from all strains of seasonal and 
pandemic influenza. Synthetic TLR agonists poorly reproduce the essential 'pattern' 
component of the larger natural ligands. To overcome this, an agonist PolyMAP, has been 
generated in which individual ligand is presented in a more natural linear pattern along the 
length of a biocompatible polymer. PolyMAP agonists can boost the immune response up to 
200 times higher on a per molecule basis. PolyMAP has three key properties that contribute 
to the enhanced adjuvant activity and safety: (1) increased receptor avidity through 
cooperative, multi-valent interactions, (2) clustering of receptors through cross-linking and 
(3) improved solubility of TLR ligands that are otherwise difficult to use in their free form. 
Recently, Kasturi et al. (Kasturi et al., 2011) have reported synthetic nanoparticle adjuvant 
that stimulates TLR4 and TLR7, ensuing in enhanced generation of antigen-specific 
antibodies by synergistic action. Hence, conferring protection to lethal viral challenges in 
mice and inducing robust immunity against the pandemic H1N1 influenza strain in Rhesus 
macaques. Researchers developed poly(d,l-lactic-co-glycolic acid) (PGLA), a biodegradable 
polymer based nanoparticle to administer the TLR4 and TLR7 ligands, it was found that in 
comparison to the stimulation of either TLR4 or TLR7 alone, the double TLR stimulation 
significantly enhanced antibody response and was found to be evident even after secondary 
immunization. 
Overall it can be concluded that adjuvants mimicking the natural molecules of viral or 
bacterial origin may be used to modulate the immune system resulting in the treatment of 
autoimmune diseases, cancers, other diseases, and when combined with vaccines, they may 
help in the generation of memory cells against a particular invader. The potential of 
adjuvant alone or as an adjuvant vaccine is yet to be fully exploited. 
11. TLRs in transplantation 
Transplantation is a surgical procedure by which cells, tissues or organs can be moved from 
one part of body to another or from one individual to another. Despite the advancement in 
surgical and medical sciences, the immune system remains the biggest barrier to 
transplantation. Till recently, the rejection of a transplant was taken as an adaptive immune 
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response mediated by killer T cells capable of inducing apoptosis as well as antibody 
secreting B cells with only small and finishing role of innate immune system like 
phagocytosis and complement activation. However, the emerging results have shown the 
importance of innate immune system in the transplant rejection via TLRs. Although direct 
role of TLRs are yet to be found but the activation of adaptive immune system because of 
TLRs may be the reason. As we know that TLRs need specific ligands to activate the 
signalling pathway and it is quite possible that during transplantation there is release of 
putative endogenous ligands such as heat shock proteins (Hsp), uric acid, hyaluronan, 
fibrinogen and chromatin (Goldstein, 2006). Some of these putative ligands have been seen 
to work with the TLRs. At the same time the role of exogenous ligands cannot be ruled out 
completely, which may be because of infection contracted while surgery. LPS from gram 
negative bacteria has been shown to activate the TLR mediated signalling pathway and 
create complications in graft or transplant acceptance. The recognition of alloantigen by 
adaptive immune system, in principle, made active because of TLRs may show increased 
level of complications on the development of cross reactivity with alloantigen and viral 
molecules. Previous studies have shown that lung, intestine and skin are more prone than 
kidney, heart and pancreas to acute rejection after transplantation (Wang et al., 2010). This 
observation may be explained that these organs which are less likely to be accepted as graft 
have commensals or pathogens, which in turn may activate innate immune system through 
TLRs leading finally to the activation of adaptive immunity. The identification of 
endogenous and control of exogenous TLR ligands may pave way for longer period of 
acceptance of transplants. 
12. TLRs in trophoblast 
During pregnancy the placenta is not only exposed to the maternal immune system, but also to 
microorganisms. It has been shown recently that in first trimester trophoblastic cells have 
TLR2 and TLR4 on their surface by which they can recognize and respond to invading 
pathogens. Interestingly, both of these TLRs show divergent response. TLR4 activation results 
in a more classical response, characterized by the induction of cytokine production whereas 
activation of TLR2 results in the induction of apoptosis. This induction of apoptosis by TLR2 
may provide a mechanism by which pathogens may give rise to complicated pregnancies in 
the first trimester, although a clear picture remains elusive. It has been seen that in several 
complicated pregnancies the case of intrauterine infection was found to be the leading cause. It 
has been seen that during first trimester TLR2 assisted trophoblastic cell apoptosis level rises. 
In turn this may give rise to several medical conditions like preterm labour, IUGR, and 
preeclampsia. Usually, the uterine infection takes place before the implantation of trophoblast. 
The pathogen gets the recognition only when it is able to penetrate the placental wall and is 
able to reach the layer where trophoblastic cells are expressing TLRs. The TLR expression is 
not limited to the cell surface but has been seen also in cytoplasm may be to facilitate 
emergency call on infection or to face the intracellular infections, if any. The TLR4 when comes 
in contact with its ligand, LPS, triggers classical response whereas TLR2 induces apoptosis by 
coming in contact with Gram positive bacterial peptidoglycan or lipoteichoic acid, but at the 
same time it has been reported that recognition of these bacterial products by TLR2 requires 
recruitment of TLR6 or TLR1. Further studies have shown that TLR6 may show increased 
effect but is not essential for TLR2 mediated response and response may be executed through 
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TLR2 homodimer or TLR1/TLR2 heterodimer. The TLR2 induces apoptotic effect through the 
activation of caspases. The TLR4 interaction with LPS does not give rise to pro-apoptotic 
signals during first trimester because the anti-apoptotic signals generated may outweigh the 
pro-apoptotic signals leading to the survival of trophoblastic cells. There is also a possibility of 
indirect induction of apoptosis due to the high level of cytokine production such as TNF and 
IFN to which placenta cells are sensitive (Vikki et al., 2006).  
13. Conclusion 
Earlier confusion of innate immunity being nonspecific as compared to adaptive immunity 
got cleared with the discovery of Toll like Receptors (TLRs) which ligate with the molecules 
having either exogenous origin like viral or bacterial or endogenous origin like Hsp. These 
ligands bear molecular patterns or signatures which make them unique for their receptors. 
The induction by these molecules may have either positive or negative effect on the body 
depending on the type of ligand and TLR. It has been seen that though ligands get 
recognised because of molecular pattern by a specific receptor, occasionally the same 
receptor may ligate with two to three different molecules with each having its own 
signature or pattern. This may be possibly due to assistance by some co-receptors. Further 
study is needed to arrive at some conclusion about this enigma. The protein-ligand complex 
crystal structures may provide insight into the still unclear picture of TLR signalling. The 
TLRs have been implicated in the development of cancers, autoimmune diseases, nervous 
system disorders and other inflammatory diseases. TLRs agonist or antagonist may help to 
get the desired result. Also their role as receptor for adjuvant alone or adjuvant vaccine is 
being explored much vigorously than before. Role of TLRs from premature birth, 
complicated pregnancies to transplant rejection cannot be ignored. Moreover, their roles 
along with miRNA need to be probed further. Also the sources of endogenous ligands need 
to be discovered. Apart from receptors, the other molecules of signalling pathway too need 
attention to understand the process much better. The need of the time is to push the TLR 
research into next level where better animal models (knockout) are ready to rule out 
artefacts. Lastly, to design drugs, vaccines and fine tune them for lesser or ideally no side 
effects. Therefore, in the light of emerging information about the complexity of TLRs in 
immune system regulation, it can be concluded that TLRs are in fact a necessary evil. 
Sometimes, from their usual behaviour as a good cop by being a part of an innate immune 
system, a first line of defence, may turn rouge due to several compelling reasons and play 
bad cop. Hence, activation of TLRs is a double edged sword in therapeutics, it has the 
potential to mount immunity against various autoimmune, inflammatory and cancerous 
diseases etc. but can also promote their development and dampen immune response against 
them. 
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